A Study Comparing an Active Drug to Placebo and to an Active Drug in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug

Brief summary

This is a Phase 3 multicenter study that includes two periods. Period 1 is designed to compare the safety, tolerability, and efficacy of an active drug Dose A once daily (QD) and Dose B QD versus placebo and versus an active drug every other week (eow) in participants with moderately to severely active Psoriatic Arthritis (PsA) and have an inadequate response to non-biologic DMARDs (DMARD-IR). Period 1 is also designed to compare the efficacy of an active drug Dose A QD and Dose B QD versus placebo for the prevention of structural progression. Period 2 evaluates the safety, tolerability and efficacy of an active drug Dose A QD and Dose B QD in participants with PsA who have completed Period 1.

Interventional study

Active, not recruiting
Psoriatic Arthritis
1705 patients
  • 1
  • 2
  • 3
  • 4
Protocol ID:
Intervention model:
Parallel Assignment
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)


Eligibility criteria

Participant attributes:
Male and Female


18 Years and older.

Inclusion Criteria:

- Clinical diagnosis of PsA with symptom onset at least 6 months prior to the Screening
Visit and fulfillment of the Classification Criteria for PsA (CASPAR) criteria.

- Participant has active disease at Baseline defined as >= 3 tender joints (based on 68
joint counts) and >= 3 swollen joints (based on 66 joint counts) at Screening and
Baseline Visits.

- Presence of either at Screening:

1. >= 1 erosion on x-ray as determined by central imaging review or;

2. high-sensitivity C-reactive protein (hs-CRP) > laboratory defined upper limit of
normal (ULN).

- Diagnosis of active plaque psoriasis or documented history of plaque psoriasis.

- Participant has had an inadequate response (lack of efficacy after a minimum 12 week
duration of therapy) to previous or current treatment with at least 1 non-biologic
DMARD at maximally tolerated dose (methotrexate (MTX), sulfasalazine (SSZ),
leflunomide (LEF), cyclosporine, apremilast, bucillamin or iguratimod), or participant
has an intolerance to or contraindication for DMARDs as defined by the investigator.

- Participant who is on current treatment with concomitant non-biologic DMARDs at study
entry must be on <= 2 non-biologic DMARDs (except the combination of MTX and
leflunomide). The following non-biologic DMARDs are allowed: MTX, sulfasalazine,
leflunomide, apremilast, hydroxychloroquine (HCQ) , bucillamine or iguratimod, and
have been ongoing for >= 12 weeks and at stable dose for >= 4 weeks prior to the
Baseline Visit. No other DMARDs are permitted during the study.

i. Participants who need to discontinue DMARDs prior to the Baseline Visit to comply
with this inclusion criterion must follow the procedure specified below or at least
five times the mean terminal elimination half-life of a drug:

1. >= 8 weeks for LEF if no elimination procedure was followed, or adhere to an
elimination procedure (i.e., 11 days with cholestyramine, or 30 days washout with
activated charcoal or as per local label);

2. >= 4 weeks for all others.

Exclusion Criteria:

- Prior exposure to any Janus Kinase (JAK) inhibitor (including but not limited to
ruxolitinib, tofacitinib, baricitinib, and filgotinib).

- Current treatment with > 2 non-biologic DMARDs; or use of DMARDs other than
methotrexate, sulfasalazine, leflunomide, apremilast, hydroxychloroquine, bucillamine,
or iguratimod; or use of methotrexate in combination with leflunomide.

- History of fibromyalgia, any arthritis with onset prior to age 17 years, or current
diagnosis of inflammatory joint disease other than PsA (including, but not limited to
rheumatoid arthritis, gout, overlap connective tissue diseases, scleroderma,
polymyositis, dermatomyositis, systemic lupus erythematosus). Prior history of
reactive arthritis or axial spondyloarthritis including ankylosing spondylitis and
nonradiographic axial spondyloarthritis is permitted if documentation of change in
diagnosis to PsA or additional diagnosis of PsA is made. Prior history of fibromyalgia
is permitted if documentation of change in diagnosis to PsA or documentation that the
diagnosis of fibromyalgia was made incorrectly.

All the cities where the clinical studies are located

Victoria - V8V 3M9
Barrie - L4M 6L2
Sainte-foy - G1V 3M7
Trois-rivières - G8Z 1Y2
Winnipeg - R3A 1M3
Winnipeg - R3N 0K6

British Columbia



More information about this study